The Medical Letter on Drugs and Therapeutics
FROM
ISSUE920
ISSUE920
April 15, 1994
Ophthalmic Levocabastine for Allergic Conjunctivitis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Ophthalmic Levocabastine for Allergic Conjunctivitis
April 15, 1994 (Issue: 920)
A 0.05% ophthalmic solution of levocabastine hydrochloride (Livostin - Iolab), a histamine H 1 -receptor antagonist, has been approved by the US Food and Drug Administration for treatment of seasonal allergic conjunctivitis. The new drug is a...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.